ReviewCurrent opinion in oncology2008
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.
Review in Current opinion in oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Targeting ferroptosis induction via nanomaterials in hepatocellular carcinoma: an insight into mechanism and therapeutic potential.Journal of nanobiotechnology · 2026Review
- Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025Review
- New and Old Key Players in Liver Cancer.International journal of molecular sciences · 2023Review
- The Novel Action of miR-193b-3p/CDK1 Signaling in HCC Proliferation and Migration: A Study Based on Bioinformatic Analysis and Experimental Investigation.International journal of genomics · 2022Article
- Complement factor H‑related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis.Molecular medicine reports · 2019Article
- Drug response prediction model using a hierarchical structural component modeling method.BMC bioinformatics · 2018Article
- Prognostic value of DNA repair based stratification of hepatocellular carcinoma.Scientific reports · 2016Article
- Astaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Κb P65 and Wnt/Β-Catenin in Vitro.Marine drugs · 2015Article
- Erratum to: Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.Medical oncology (Northwood, London, England) · 2015Article
- Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.Medical oncology (Northwood, London, England) · 2014Article
- Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.BioMed research international · 2014Review
- Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.World journal of gastroenterology · 2012Review
- Cancer module genes ranking using kernelized score functions.BMC bioinformatics · 2012Article
- The functional cancer map: a systems-level synopsis of genetic deregulation in cancer.BMC medical genomics · 2011Article
- Targeted therapies for hepatocellular carcinoma.Gastroenterology · 2011Review
- Exploring genomic profiles of hepatocellular carcinoma.Molecular carcinogenesis · 2011Review
- An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.Science translational medicine · 2010Article
- New strategies in hepatocellular carcinoma: genomic prognostic markers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
- Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling.Hepatology (Baltimore, Md.) · 2010Article
- Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.Seminars in liver disease · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewThe development of high-throughput technologies able to simultaneously investigate thousands of genes (e.g. single nucleotide polymorphism-array, gene expression microarray, etc.) has opened a new era in translational research. Obtaining a molecular classification of hepatocellular carcinoma, however, remains a striking challenge. This review summarizes the molecular classifications of hepatocellular carcinoma reported so far, analyzes the status of targeted therapies tested in clinical trials, and evaluates feasibility of personalized medicine approaches in hepatocellular carcinoma. RECENT
findingsDifferent investigators attempted to classify patients according to their liver cancer molecular background, a feature that will path the way for trial enrichment and personalized medicine. Currently, hepatocellular carcinoma can be classified in molecular classes according to Wnt-beta-catenin pathway activation, proliferation signature activation (associated with chromosomal instability), and other subgroups. In parallel, the first-time-ever positive results of a phase III trial in advanced hepatocellular carcinoma with the multikinase inhibitor sorafenib have encouraged this approach. SUMMARY: Selection of patient candidates according to their tumor molecular background is a reality in human malignancies. Thus, a molecular classification is essential to allow the development of new targets, and to customize therapies in patients with hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.